La vendita allo scoperto per Rezolute dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Rezolute. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Rezolute (NASDAQ:RZLT) Azioni, Report sulle vendite allo scoperto

Rezolute

Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.

Rezolute Inc

<p>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45) by 17.78 percent. This is a 32.73 percent increase over losses of $(0.55) per share from the same period last year.  The company reported quarterly sales of $791.00 thousand which missed the analyst consensus estimate of $2.02 million by 60.84 percent.  This is a 434.46 percent increase over sales of $148.00 thousand the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

News

IPSC

Century Therapeutics Q3 EPS $(0.37) Beats $(0.45) Estimate, Sales $791.00K Miss $2.02M Estimate

Yum Brands Earlier Reported Q3 Sales $1.826B Miss $1.899B Estimate

Contracts

NTRP

NextTrip Announced It Has Signed A Non-Binding Letter Of Intent To Acquire Five Star Alliance; Terms Not Disclosed

<p><i>– Rapid responses and symptom improvement observed in inflammatory and fibrotic manifestations of chronic GVHD in heavily pretreated patients –</i></p>
<p>WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>), today announced that multiple abstracts evaluating Niktimvo&#x2122; (axatilimab-csfr), an anti-CSF-1R antibody for the treatment of chronic graft-versus-host disease (GVHD), have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting being held in San Diego, California, December 7-10, 2024. The presentations will highlight a secondary analysis of overall and organ-specific responses and findings from an exposure-response analysis in patients with chronic GVHD from the pivotal Phase 2 AGAVE-201 trial of Niktimvo, as well as preclinical data further characterizing the Niktimvo mechanism of action.</p>


Biotech

General

SNDX

Syndax Announces New Data From Secondary Analysis Of The Pivotal AGAVE-201 Trial Of Niktimvo In Chronic Graft-Versus-Host Disease To Be Presented At 66th ASH Annual Meeting

<p>Brookfield Infr Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIP#NYSE">BIP</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Brookfield Infr Partners will report an <strong>earnings per share</strong> (EPS) of $0.14.</p>
<p>The announcement from Brookfield Infr Partners is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.26, leading to a 2.22% drop in the share price the following trading session.</p>
<p>Here's a look at Brookfield Infr Partners's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.16</td>
<td>0.11</td>
<td>0.18</td>
<td>0.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.10</td>
<td>0.10</td>
<td>0.36</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815498_0.png" alt="eps graph" /></p>
<h3>Analyst Opinions on Brookfield Infr Partners</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Brookfield Infr Partners.</p>
<p>The consensus rating for Brookfield Infr Partners is Buy, derived from 1 analyst ratings. An average one-year price target of $39.0 implies a potential 15.04% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of CenterPoint Energy, CMS Energy and Ameren, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, CenterPoint Energy is favoring an Neutral trajectory, with an average 1-year price target of $29.62, suggesting a potential 12.63% downside.</li>
<li>CMS Energy received a Outperform consensus from analysts, with an average 1-year price target of $72.43, implying a potential 113.66% upside.</li>
<li>As per analysts' assessments, Ameren is favoring an Neutral trajectory, with an average 1-year price target of $89.0, suggesting a potential 162.54% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for CenterPoint Energy, CMS Energy and Ameren, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NiSource</td>
<td>Outperform</td>
<td>4.76%</td>
<td>$553M</td>
<td>1.06%</td>
</tr>
<tr>
<td>CenterPoint Energy</td>
<td>Neutral</td>
<td>-0.22%</td>
<td>$883M</td>
<td>1.85%</td>
</tr>
<tr>
<td>CMS Energy</td>
<td>Outperform</td>
<td>4.18%</td>
<td>$739M</td>
<td>3.20%</td>
</tr>
<tr>
<td>Ameren</td>
<td>Neutral</td>
<td>-3.81%</td>
<td>$868M</td>
<td>2.25%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Brookfield Infr Partners ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.</p>
<h3>Unveiling the Story Behind Brookfield Infr Partners</h3>
<p>Brookfield Infrastructure Partners LP is a Bermuda exempted limited partnership that owns and operates quality, long-life assets that generate stable cash flows, by virtue of barriers to entry or other characteristics that tend to appreciate in value over time. It focuses on acquiring infrastructure assets that have low maintenance capital costs and high barriers to entry. The company's segments consist of Utilities, Transport, Midstream, and Data. Geographically, it generates maximum revenue from Canada and also has a presence in Australia, Colombia, United Kingdom, Brazil, United States of America, Chile, Peru, and other countries.</p>
<h3>Key Indicators: Brookfield Infr Partners's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Brookfield Infr Partners's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>20.72%</strong> as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Utilities sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-0.74%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Brookfield Infr Partners's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-0.64%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Brookfield Infr Partners's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.04%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>8.52</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/BIP/earnings"><strong>To track all earnings releases for Brookfield Infr Partners visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For Brookfield Infr Partners

WIIM

Fabrinet shares are trading lower following Q1 financial results.

<p>Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Macerich to report an <strong>earnings per share</strong> (EPS) of $0.40.</p>
<p>The announcement from Macerich is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.03, leading to a 3.12% drop in the share price the following trading session.</p>
<p>Here's a look at Macerich's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.40</td>
<td>0.39</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.37</td>
<td>0.31</td>
<td>0.56</td>
<td>0.44</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Macerich Share Price Analysis</h3>
<p>Shares of Macerich were trading at $18.67 as of November 01. Over the last 52-week period, shares are up 82.68%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about Macerich</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Macerich.</p>
<p>Macerich has received a total of 4 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $15.9, the consensus suggests a potential 14.84% downside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Tanger, Phillips Edison and Acadia Realty Trust, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Neutral trajectory for Tanger, with an average 1-year price target of $32.5, indicating a potential 74.08% upside.</li>
<li>Phillips Edison is maintaining an Neutral status according to analysts, with an average 1-year price target of $36.67, indicating a potential 96.41% upside.</li>
<li>The consensus among analysts is an Neutral trajectory for Acadia Realty Trust, with an average 1-year price target of $24.33, indicating a potential 30.32% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>In the peer analysis summary, key metrics for Tanger, Phillips Edison and Acadia Realty Trust are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macerich</td>
<td>Neutral</td>
<td>1.48%</td>
<td>$116.03M</td>
<td>10.52%</td>
</tr>
<tr>
<td>Tanger</td>
<td>Neutral</td>
<td>16.55%</td>
<td>$91.41M</td>
<td>4.44%</td>
</tr>
<tr>
<td>Phillips Edison</td>
<td>Neutral</td>
<td>8.56%</td>
<td>$118.43M</td>
<td>0.51%</td>
</tr>
<tr>
<td>Acadia Realty Trust</td>
<td>Neutral</td>
<td>7.81%</td>
<td>$62.21M</td>
<td>0.44%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Macerich ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>About Macerich</h3>
<p>The Macerich Company invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and 14 regional malls in its unconsolidated portfolio along with three power centers and seven other real estate assets. The company's total portfolio has 45.5 million square feet of gross leasable area and averaged $836 sales per square foot over the 12 months ended in December 2023.</p>
<h3>Financial Milestones: Macerich's Journey</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Macerich's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>1.48%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Macerich's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>116.93%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Macerich's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>10.52%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Macerich's ROA excels beyond industry benchmarks, reaching <strong>3.33%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Macerich's debt-to-equity ratio is below the industry average. With a ratio of <b>1.85</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/MAC/earnings"><strong>To track all earnings releases for Macerich visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights into Macerich's Upcoming Earnings

<p>Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Johnson Controls Intl will report an <strong>earnings per share</strong> (EPS) of $1.20.</p>
<p>Johnson Controls Intl bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.05, leading to a 1.69% drop in the share price the following trading session.</p>
<p>Here's a look at Johnson Controls Intl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.09</td>
<td>0.75</td>
<td>0.51</td>
<td>1.09</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.14</td>
<td>0.78</td>
<td>0.51</td>
<td>1.05</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815456_0.png" alt="eps graph" /></p>
<h3>Analyst Opinions on Johnson Controls Intl</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Johnson Controls Intl.</p>
<p>A total of 8 analyst ratings have been received for Johnson Controls Intl, with the consensus rating being Neutral. The average one-year price target stands at $79.75, suggesting a potential 7.44% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>The below comparison of the analyst ratings and average 1-year price targets of Carrier Global, Lennox Intl and Builders FirstSource, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Carrier Global, with an average 1-year price target of $82.06, suggesting a potential 10.55% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Lennox Intl, with an average 1-year price target of $630.57, suggesting a potential 749.48% upside.</li>
<li>Builders FirstSource is maintaining an Buy status according to analysts, with an average 1-year price target of $206.47, indicating a potential 178.15% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Carrier Global, Lennox Intl and Builders FirstSource are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson Controls Intl</td>
<td>Neutral</td>
<td>1.37%</td>
<td>$2.49B</td>
<td>6.17%</td>
</tr>
<tr>
<td>Carrier Global</td>
<td>Neutral</td>
<td>21.26%</td>
<td>$1.68B</td>
<td>3.14%</td>
</tr>
<tr>
<td>Lennox Intl</td>
<td>Neutral</td>
<td>9.65%</td>
<td>$488.40M</td>
<td>35.90%</td>
</tr>
<tr>
<td>Builders FirstSource</td>
<td>Buy</td>
<td>-1.60%</td>
<td>$1.46B</td>
<td>7.43%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Johnson Controls Intl ranks in the middle for consensus rating. It ranks at the bottom for revenue growth. It ranks in the middle for gross profit. It ranks at the bottom for return on equity.</p>
<h3>Get to Know Johnson Controls Intl Better</h3>
<p>Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration units, and fire and security solutions. Commercial HVAC accounts for over 45% of sales, fire and security represents roughly 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 15% of revenue. In fiscal 2023, Johnson Controls generated nearly $27 billion in revenue.</p>
<h3>Financial Insights: Johnson Controls Intl</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Johnson Controls Intl showcased positive performance, achieving a revenue growth rate of <strong>1.37%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Johnson Controls Intl's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>13.48%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Johnson Controls Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>6.17%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Johnson Controls Intl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>2.25%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Johnson Controls Intl's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.65</strong>.</p>
<p><a href="https://www.benzinga.com/quote/JCI/earnings"><strong>To track all earnings releases for Johnson Controls Intl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Examining the Future: Johnson Controls Intl's Earnings Outlook

Events

AUTL

Autolus Therapeutics To Present Clinical Data Updates At ASH Annual Meeting 2024

CRSP

CRISPR Therapeutics Q3 EPS $(1.01) Beats $(1.42) Estimate, Sales $602.00K

Louisiana-Pacific shares are trading higher following better-than-expected Q3 financial results.

<p>Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-06. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Paycor HCM will report an <strong>earnings per share</strong> (EPS) of $0.08.</p>
<p>The market awaits Paycor HCM's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 9.5% increase in the share price the next day.</p>
<p>Here's a look at Paycor HCM's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.09</td>
<td>0.20</td>
<td>0.09</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.11</td>
<td>0.21</td>
<td>0.11</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>10.0%</td>
<td>-16.0%</td>
<td>5.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815432_0.png" alt="eps graph" /></p>
<h3>Market Performance of Paycor HCM's Stock</h3>
<p>Shares of Paycor HCM were trading at $15.71 as of November 01. Over the last 52-week period, shares are down 11.99%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PYCR/earnings"><strong>To track all earnings releases for Paycor HCM visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PYCR

Earnings Preview For Paycor HCM

<p>Barclays  analyst Julian Mitchell   maintains Gates Industrial Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTES#NYSE">GTES</a>) with a Equal-Weight and raises the price target from $16 to $21.</p>


Price Target

Analyst Ratings

GTES

Barclays Maintains Equal-Weight on Gates Industrial Corp, Raises Price Target to $21

<p>Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Gilead Sciences to report an <strong>earnings per share</strong> (EPS) of $1.55.</p>
<p>Gilead Sciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.41, leading to a 2.55% drop in the share price on the subsequent day.</p>
<p>Here's a look at Gilead Sciences's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.60</td>
<td>-1.49</td>
<td>1.78</td>
<td>1.92</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.01</td>
<td>-1.32</td>
<td>1.72</td>
<td>2.29</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>0.0%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815412_0.png" alt="eps graph" /></p>
<h3>Performance of Gilead Sciences Shares</h3>
<p>Shares of Gilead Sciences were trading at $89.84 as of November 04. Over the last 52-week period, shares are up 15.33%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Gilead Sciences</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Gilead Sciences.</p>
<p>The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Vertex Pharmaceuticals, Regeneron Pharmaceuticals and Amgen, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Vertex Pharmaceuticals, with an average 1-year price target of $495.09, implying a potential 451.08% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Regeneron Pharmaceuticals, with an average 1-year price target of $1172.19, indicating a potential 1204.75% upside.</li>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Amgen, with an average 1-year price target of $347.8, implying a potential 287.13% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Vertex Pharmaceuticals, Regeneron Pharmaceuticals and Amgen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilead Sciences</td>
<td>Neutral</td>
<td>5.36%</td>
<td>$5.41B</td>
<td>9.01%</td>
</tr>
<tr>
<td>Vertex Pharmaceuticals</td>
<td>Neutral</td>
<td>6.11%</td>
<td>$2.27B</td>
<td>-21.57%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals</td>
<td>Outperform</td>
<td>10.65%</td>
<td>$3.23B</td>
<td>4.66%</td>
</tr>
<tr>
<td>Amgen</td>
<td>Neutral</td>
<td>23.18%</td>
<td>$5.19B</td>
<td>42.08%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Gilead Sciences ranks in the middle for revenue growth among its peers. It has the highest gross profit margin. The company's return on equity is higher than two peers and lower than one. Overall, Gilead Sciences is positioned competitively within its peer group based on these metrics.</p>
<h3>Delving into Gilead Sciences's Background</h3>
<p>Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).</p>
<h3>Gilead Sciences: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Gilead Sciences showcased positive performance, achieving a revenue growth rate of <strong>5.36%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Gilead Sciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>23.21%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Gilead Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>9.01%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>2.94%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.28</strong>.</p>
<p><a href="https://www.benzinga.com/quote/GILD/earnings"><strong>To track all earnings releases for Gilead Sciences visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GILD

Gilead Sciences's Earnings: A Preview

BLNK

Blink Charging Establishes £100M Special Purpose Vehicle For EV Charger Expansion, Partnering With Axxeltrova Capital To Drive Infrastructure Growth And Attract Sustainable Investment

<p><strong>Sun Communities</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-11-06. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Sun Communities will report an <strong>earnings per share</strong> (EPS) of $2.52. </p>
<p>The market awaits Sun Communities's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company's EPS missed by $0.02 in the last quarter, leading to a 5.11% increase in the share price on the following day.</p>
<p>Here's a look at Sun Communities's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.88</td>
<td>1.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.86</td>
<td>1.19</td>
<td>1.34</td>
<td>2.57</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>5.0%</td>
<td>-7.000000000000001%</td>
<td>2.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of Sun Communities were trading at $130.28 as of November 04. Over the last 52-week period, shares are up 11.3%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Sun Communities</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Sun Communities.</p>
<p>The consensus rating for Sun Communities is Neutral, derived from 7 analyst ratings. An average one-year price target of $148.57 implies a potential 14.04% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Equity Lifestyle Props, American Homes 4 Rent and Invitation Homes, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Equity Lifestyle Props, with an average 1-year price target of $75.0, implying a potential 42.43% downside.</li>
<li>For American Homes 4 Rent, analysts project an Neutral trajectory, with an average 1-year price target of $42.11, indicating a potential 67.68% downside.</li>
<li>Invitation Homes received a Neutral consensus from analysts, with an average 1-year price target of $38.17, implying a potential 70.7% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Equity Lifestyle Props, American Homes 4 Rent and Invitation Homes, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sun Communities</td>
<td>Neutral</td>
<td>1.09%</td>
<td>$395.90M</td>
<td>0.75%</td>
</tr>
<tr>
<td>Equity Lifestyle Props</td>
<td>Neutral</td>
<td>-0.64%</td>
<td>$174.24M</td>
<td>5.78%</td>
</tr>
<tr>
<td>American Homes 4 Rent</td>
<td>Neutral</td>
<td>5.54%</td>
<td>$241.05M</td>
<td>1.05%</td>
</tr>
<tr>
<td>Invitation Homes</td>
<td>Neutral</td>
<td>6.90%</td>
<td>$383.71M</td>
<td>0.95%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Sun Communities is positioned in the middle among its peers for revenue growth. It ranks at the bottom for gross profit and return on equity.</p>
<h3>All You Need to Know About Sun Communities</h3>
<p>Sun Communities is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently owns a portfolio of 666 properties, which includes 350 manufactured housing communities, 179 residential vehicle communities, and 137 marina properties. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.</p>
<h3>Financial Insights: Sun Communities</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Sun Communities's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>1.09%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.</p>
<p><strong>Net Margin:</strong> Sun Communities's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>6.03%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Sun Communities's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.75%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.3%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.14</strong>.</p>
<p><a href="https://www.benzinga.com/quote/SUI/earnings"><strong>To track all earnings releases for Sun Communities visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What to Expect from Sun Communities's Earnings

TTEK

Tetra Tech Announced That The Defense Logistics Agency Selected The Company For Its $12B J6 Enterprise Technology Services Award Contract

<p>GFL Environmental (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFL#NYSE">GFL</a>) is preparing to release its quarterly earnings on Wednesday, 2024-11-06. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect GFL Environmental to report an <strong>earnings per share</strong> (EPS) of $0.25.</p>
<p>Investors in GFL Environmental are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 3.32% increase in the share price the following trading session.</p>
<p>Here's a look at GFL Environmental's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.22</td>
<td>-0.02</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.21</td>
<td>0</td>
<td>0.04</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>5.0%</td>
<td>-3.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815392_0_0.png" alt="eps graph" /></p>
<h3>Market Performance of GFL Environmental's Stock</h3>
<p>Shares of GFL Environmental were trading at $41.36 as of November 01. Over the last 52-week period, shares are up 43.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/GFL/earnings"><strong>To track all earnings releases for GFL Environmental visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: GFL Environmental's Earnings

<p>Ratings for Lithia Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAD#NYSE">LAD</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $353.5, a high estimate of $405.00, and a low estimate of $299.00. This upward trend is evident, with the current average reflecting a 12.85% increase from the previous average price target of $313.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730815385_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Lithia Motors. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Ali Faghri</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$380.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$343.00</td>
<td>$299.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$299.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Adam Jonas</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$310.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Jeff Lick</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$360.00</td>
<td>-</td>
</tr>
<tr>
<td>Rajat Gupta</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Ali Faghri</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$338.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lithia Motors. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Lithia Motors compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Lithia Motors's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Lithia Motors's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LAD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lithia Motors analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Lithia Motors</h2>
<p>Lithia Motors is a retailer of new and used vehicles and related services. The company offers over 50 brands of vehicles at nearly 500 stores globally across the US, Canada, and UK. The company has expanded largely through the acquisition of dealerships in smaller regional markets but now seeks to grow in any part of the US and we expect more deals over time in the US and, at times, abroad. Annual revenue in 2023 was $31 billion and we see over $50 billion possible in a few years. The US was 90% of 2023 revenue and the UK second at 6%, the latter should rise to around 20% with the 2024 Pendragon acquisition. In 2023, new-car sales were about 49% of total revenue. Lithia was founded in 1946, went public in 1996, and is the largest US auto dealer. It is based in Medford, Oregon.</p>
<h3>Breaking Down Lithia Motors's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Lithia Motors's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>11.41%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>2.27%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Lithia Motors's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>3.22%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Lithia Motors's ROA excels beyond industry benchmarks, reaching <strong>0.9%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Lithia Motors's debt-to-equity ratio is below the industry average at <strong>2.13</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Critical Insights From Lithia Motors Analyst Ratings: What You Need To Know

<p>Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Genmab to report an <strong>earnings per share</strong> (EPS) of $0.35.</p>
<p>The market awaits Genmab's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS missed by $0.02, leading to a 2.36% drop in the share price on the subsequent day.</p>
<p>Here's a look at Genmab's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.33</td>
<td>0.14</td>
<td>4.02</td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.29</td>
<td>0.36</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>7.000000000000001%</td>
<td>2.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Market Performance of Genmab's Stock</h3>
<p>Shares of Genmab were trading at $22.78 as of November 04. Over the last 52-week period, shares are down 26.52%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Genmab</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Genmab.</p>
<p>A total of 10 analyst ratings have been received for Genmab, with the consensus rating being Buy. The average one-year price target stands at $46.2, suggesting a potential 102.81% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Incyte, Natera and Exact Sciences, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Neutral trajectory for Incyte, with an average 1-year price target of $72.88, indicating a potential 219.93% upside.</li>
<li>The prevailing sentiment among analysts is an Outperform trajectory for Natera, with an average 1-year price target of $140.15, implying a potential 515.23% upside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Exact Sciences, with an average 1-year price target of $83.33, indicating a potential 265.8% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>In the peer analysis summary, key metrics for Incyte, Natera and Exact Sciences are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genmab</td>
<td>Buy</td>
<td>29.58%</td>
<td>$5.21B</td>
<td>4.44%</td>
</tr>
<tr>
<td>Incyte</td>
<td>Neutral</td>
<td>23.81%</td>
<td>$1.05B</td>
<td>3.45%</td>
</tr>
<tr>
<td>Natera</td>
<td>Outperform</td>
<td>58.13%</td>
<td>$243.17M</td>
<td>-4.59%</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Outperform</td>
<td>12.41%</td>
<td>$509.46M</td>
<td>-0.50%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Genmab ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.</p>
<h3>Unveiling the Story Behind Genmab</h3>
<p>Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson &amp; Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson &amp; Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.</p>
<h3>Key Indicators: Genmab's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Genmab displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>29.58%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Genmab's net margin excels beyond industry benchmarks, reaching <strong>26.06%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.44%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Genmab's ROA excels beyond industry benchmarks, reaching <strong>3.74%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Genmab adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/GMAB/earnings"><strong>To track all earnings releases for Genmab visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


GMAB

Preview: Genmab's Earnings

Rezolute ( ($RZLT) ) has issued an update. Rezolute, Inc. has made a significant leap forward as the FDA removes all partial clinical holds on thei...

Rezolute's RZ358 Advances with FDA Clearance for Study

Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy

Rezolute (RZLT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Butler from JMP Secur...

Rezolute's RZ358 Advances: FDA Clearance and Positive Trial Outlook Justify Buy Rating

Rezolute (RZLT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wain...

Rezolute Buy Rating Affirmed: RZ358 Clinical Advancements and Strong Market Potential

Maxim Group analyst Jason McCarthy has maintained their bullish stance on RZLT stock, giving a Buy rating yesterday. Jason McCarthy has given his B...

Rezolute's Drug Pipeline Progress and FDA Hold Lift Propel Buy Rating and Increased Price Target

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Rezolute (RZLT – Research Report), retaining the price target of $7.00. Jason But...

Buy Rating Affirmed for Rezolute Amidst Progressive Clinical Trials and Strong Financial Position

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rezolute (RZLT – Research Report) and Gryphon Digi...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Rezolute (RZLT) and Gryphon Digital Mining (GRYP)

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Rezolute (RZLT – Research Report), retaining the price target of $14.00. Douglas...

Buy Rating Affirmed for Rezolute on Strong Clinical Progress and Strategic Pipeline Development

Rezolute (RZLT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Edward Nash from Canacc...

Edward Nash Recommends Buy on Rezolute, Sets $9 Target Amidst Product Progress and Regulatory Advancements

Wedbush initiated coverage of Rezolute (RZLT) with an Outperform rating and $12 price target Published first on TheFly – the ultimate source for re...

Rezolute initiated with an Outperform at Wedbush

GRYP

RZLT

Health Care

Press Releases

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Comments

Rezolute

Vendite allo scoperto

Rezolute (NASDAQ:RZLT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO